Drugs / GPI-0100
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00329368 | Sep 2005 → Dec 2007 | cancer | Endocyte | Completed | No outcome recorded |
| Phase 1 | NCT00016146 | Jul 2000 → Mar 2009 | prostate cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
Also used as a comparator or background therapy in 3 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01880411 Background | Jun 2013 → Jan 2014 | cervical intraepithelial neoplasia | HealthBanks Biotech Co., Ltd. | Unknown | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT02576561 Comparator | Nov 2015 → May 2018 | cervical intraepithelial neoplasia grade 2/3, human papilloma virus infection | THEVAX Genetics Vaccine | Unknown | No outcome recorded |
| Phase 2 | NCT00485563 Background | Jun 2007 → Aug 2008 | renal cell carcinoma | Endocyte | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GPI-0100 | “PEK (PE-E7-K3), a recombinant protein combined with GPI-0100 adjuvant” NCT01880411 ↗ |
| Modality | Other / unclassified | “GPI-0100 adjuvant (a drug intended to improve antibody production)” NCT00485563 ↗ |
| Route | Subcutaneous | “Patients receive glycosylated MUC-2-Globo H-KLH conjugate vaccine with adjuvant GPI-0100 subcutaneously weekly on weeks 0-2, 6, 14, and 26” NCT00016146 ↗ |